Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

Immunotherapy with programmed death-1(PD-1) inhibitors is now standard therapy for first-line use in patients with driver-negative advanced NSCLC, whether as single-agent or in combination with chemotherapy. After progression of first-line immunotherapy, NSCLC patients may be treated with chemotherapy, radiotherapy or targeted therapies, among others. Recently, Immune Checkpoint inhibitors (ICIs) rechallenge has become a highly anticipated option. Although the objective response rate of the ICIs rechallenge patients has decreased substantially compared with the efficacy of the first ICI treatm

Trial Details

NCT ID

NCT06127303

Phase

PHASE2

Sponsor

Shanghai Chest Hospital

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Toripalimab
Cryoablation

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806
Shanghai, China|31.22222,121.45806
Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Voluntary participation and written informed consent;
histologically or cytologically confirmed advanced metastatic (stage IV) non-small cell lung cancer;
Patients with negative driver genes who develop oligoprogression after receiving standard first-line therapy. The oligoprogression is defined as: 1…
Age 18-75 years old; ECOG PS: 0-1; The expected survival is more than 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →